Research on cancer as a disease, from cause to care. Covers tumor biology, small-cell lung cancer, cancer-linked stroke risk, and cancer center research.
A Rice University-led research team is working on a new approach to treat acute myeloid leukemia (AML) by targeting the energy-producing mitochondria of cancer cells. By disrupting mitochondrial function, the researchers aim to selectively kill AML cells while leaving healthy blood cells unharmed.
Researchers developed self-propelled ferroptosis nanoinducers to enhance cancer therapy by inducing programmed cell death. The nanotherapeutics exhibited enhanced diffusion and deep tumor penetration while maintaining biocompatibility.
Dr. Nikolaos Koundouros has been awarded the 2025 Tri-Institutional Breakout Award for his research on how cells detect and respond to dietary nutrients, specifically omega-6 and omega-3 fatty acids, in relation to breast cancer development.
A five-year analysis of the CheckMate-816 clinical trial shows that immunotherapy plus chemotherapy before lung cancer surgery significantly improves long-term survival. Patients who achieved complete remission had a 95% five-year survival rate.
Researchers discovered that blocking PRDX1 protein can make ovarian cancer cells more responsive to DNA-damaging platinum therapies. The study suggests targeting PRDX1 could be a viable strategy to improve chemotherapy efficacy.
A team at IRB Barcelona developed a tool to generate customized aneuploidies, precisely labeling cells carrying these abnormalities in living tissue. This allows for real-time observation of cell behavior, revealing the presence of haploinsufficient genes and their removal through cell competition.
A high-fiber plant-based diet improved health markers that could delay the progression of precancerous conditions and multiple myeloma. The study showed significant improvements in dietary quality, weight loss, metabolic markers, inflammation, and gut microbiome diversity.
Researchers used canine DNA to identify over 15 genes linked to gastric cancer in humans, offering promising new avenues for research. The study suggests genetic testing could help diagnose the disease earlier and guide breeding decisions to reduce disease prevalence.
Rapid advances in cancer treatment have improved long-term survival rates, but current resources and models of care in Canada do not meet the changing needs of people with cancer. The authors propose solutions such as reducing unnecessary surveillance and establishing interdisciplinary specialty clinics.
Combining immunotherapy drug dostarlimab with standard chemotherapy improved survival and reduced symptoms in patients with advanced endometrial cancer. Patients lived up to 5.5 months longer with fewer side effects, outweighing risks.
A recent randomized controlled trial found that a group-based intervention fostering communication and coping skills in a culturally tailored way improved outcomes for Latina breast cancer survivors and their caregivers. The study, published in CANCER journal, demonstrated high engagement among participants and clinically significant i...
Researchers identified the PROX1 gene as an early driver of prostate cancer aggression, which leads to treatment-resistant tumors. The team found that a class of FDA-approved drugs, HDAC inhibitors, can disable PROX1 and reduce tumor survival in aggressive prostate cancer subtypes.
A global clinical trial led by Irish cancer specialist Prof. Patrick Forde shows that immunotherapy with chemotherapy before lung cancer surgery reduces the risk of cancer returning and improves long-term survival. The study found that patients who received immunotherapy plus chemotherapy had improved outcomes compared to those who rec...
A new study from Fox Chase Cancer Center researchers found that implementing a Best Practice Advisory in the electronic medical record system increased oncofertility referrals by 450%. This led to 14 successful fertility preservation cases within six months, compared to just 22 in the previous five years.
Charité researchers identified a therapeutic target that significantly contributes to halting ongoing inflammatory processes. They found that interleukin-22 and oncostatin M drive inflammation by amplifying the immune response. Targeted treatments may help high-risk patients, but chronic diseases remain complex and difficult to predict.
A phase 2 trial found that combining avelumab and cetuximab significantly extended median progression-free survival in patients with advanced cutaneous squamous cell carcinoma. The combination showed synergistic effects, suggesting a potential new standard of care for this patient population.
The ASCENT-04/KEYNOTE-D19 study shows that sacituzumab govitecan plus pembrolizumab improves progression-free survival and response rates compared to chemotherapy. Nearly 60% of patients responded, with durable responses lasting up to 16.6 months.
The American Cancer Society estimates that 18.6 million people in the US live with a history of cancer as of January 1, 2025, and this number is projected to increase to over 22 million by 2035. The study highlights notable disparities in treatment for common cancers, including lung and colorectal cancer.
DB-1310, a HER3-targeted antibody-drug conjugate, has shown real potential as a new treatment option for patients with advanced solid tumors that have progressed after standard therapies. In an international clinical trial, DB-1310 demonstrated significant tumor shrinkage and delayed cancer growth in 44% of EGFR-mutant NSCLC patients.
Researchers discovered a specialized histone arrangement, called the CENP-A–H4 octasome, in centromeric regions. This unique structure likely contributes to proper kinetochore formation and mitosis.
A new app, BMT-CARE App, was tested in a randomized clinical trial to help caregivers manage stress and emotions related to bone marrow transplant patients. The app showed significant improvements in quality of life, burden, and mood symptoms compared to standard services.
A new study from University of Illinois Chicago researchers suggests that poorly functioning blood vessels may be the cause of muscle wasting in cancer patients. The discovery could lead to the development of targeted therapies to restore blood vessel health and improve muscle strength.
Researchers identified four areas of support needed for adolescent and young adult cancer patients: school accommodations, extracurricular activities, academic trajectory, and social connections. Supporting scholastic performance can help mitigate negative impacts on mental health and financial security.
Weill Cornell Medicine researchers Dr. Juan R. Cubillos-Ruiz and Dr. David Lyden have been awarded a $750,000 grant to study ovarian cancer, with a focus on harnessing immune cells and detecting the disease earlier. Their research aims to develop innovative strategies for eliminating metastatic tumors and preventing recurrence.
Researchers at Virginia Tech's Fralin Biomedical Research Institute developed a peptide therapy called JM2 that targets cancer cells' ability to renew and regrow. The treatment significantly slows tumor growth in animal models and disrupts the maintenance of treatment-resistant cancer cells.
A multi-center clinical trial found that Duavee, a menopause drug, significantly reduced cell growth in breast tissue and was well-tolerated by participants. The study suggests that Duavee may offer a promising alternative for women at elevated risk of invasive breast cancer due to personal or family history.
A new study analyzed trends over time in alcohol-linked cancer mortality across the US, finding nearly double the number of alcohol-related cancer deaths between 1990 and 2021. The burden is highest among men over 55, with liver, colorectal, and esophageal cancers seeing significant increases.
Researchers from Anglia Ruskin University and Imperial College London used advanced paleoproteomic techniques to analyze dinosaur fossils, discovering red blood cell-like structures in a fossil. This finding raises the possibility that soft tissue and cellular components are more commonly preserved in ancient remains than previously th...
A study found that fewer than half of U.S. adults are aware of the link between alcohol and cancer, highlighting a need for increased awareness and action. The findings emphasize the importance of reducing the alcohol-related cancer burden in the US.
The National Comprehensive Cancer Network (NCCN) honors individuals who champion access to high-quality, patient-centered cancer care. This year's recipients include Drs. Nadeem Abu-Rustum and Louis Nabors for their excellence in engagement and dedication to shaping cancer treatment recommendations.
The foundation recognizes five early-career scientists who apply computational methods to cancer research, with a focus on developing new protein designs and understanding chromatin modifications. Their work aims to improve treatment strategies and precision oncology for various cancers.
Researchers discovered biomarkers in gut bacteria and metabolites that can help diagnose and treat gastrointestinal diseases. The study found that certain biomarkers could predict multiple diseases, including gastric cancer and inflammatory bowel disease.
Researchers identified a new biomarker, TTF-1, that predicts survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib. Patients with low TTF-1 levels responded poorly to sotorasib, while those with high TTF-1 levels showed improved outcomes.
Researchers from Mayo Clinic Comprehensive Cancer Center will present practice-changing studies on chemotherapy approaches, AI applications in oncology, and new therapies for breast and melanoma. The event will feature 59 abstracts highlighting advancements in cancer care.
Researchers identify five distinct immunotypes in tongue squamous cell carcinoma, shedding light on why current immunotherapies fail. The study's findings highlight the need for immune-based assessments to guide treatment decisions and suggest a new approach to personalized medicine.
The study found that teenagers experienced the longest median time to diagnosis (8.7 weeks), while infants under one year had the shortest (3.7 weeks). Bone tumours were associated with a longer diagnostic interval, highlighting the need for faster diagnoses in certain groups.
The University of Houston has launched a $3M Cancer Immunotherapy Biomarker Core to accelerate early diagnosis and treatment response in cancer. The core will offer comprehensive targeted proteomic cancer biomarker screens, enabling researchers to identify better biomarkers for cancer.
Autophagy and lysosomal pathways orchestrate the unconventional secretion of PARK7, a PD-associated protein, in response to cellular stress. The study reveals a unique mechanism involving coordinated actions of macroautophagy and chaperone-mediated autophagy.
Researchers discovered a novel mechanism by which glioblastoma cells exploit astrocytes to evade immune responses. The study highlights an astrocyte-driven mechanism used by GBM to escape protective immune responses and could guide novel immunotherapies for the treatment of this aggressive brain cancer.
The European Society for Medical Oncology (ESMO) has released the latest version of the ESMO-MCBS scale, which measures the clinical benefit of cancer treatments. The new version incorporates 13 critical amendments to improve evaluation and accuracy, with a focus on patient preferences and toxicity annotations.
A study published in PNAS reveals that colorectal cancer cells utilize a protein called TBX3, which regulates embryo development, to contribute to their aggressiveness and metastasis. The discovery opens up possibilities for developing targeted therapies to prevent tumor cell spread.
Researchers at UC San Diego develop new approach using artificial intelligence to predict therapy outcomes and match patients with right treatments, improving cancer care and patient outcomes.
Four Weill Cornell Medicine investigators received the Ritu Banga Healthcare Disparities Research Awards to tackle disparities in cancer care, racial and ethnic differences in pediatric Hodgkin lymphoma, and access barriers to high-quality surgical cancer care. The awards support innovative research aimed at improving health outcomes f...
Researchers from MD Anderson Cancer Center present notable studies on immunotherapy and CAR T cell therapy for various cancer types. These findings show promising results for patients with aggressive and rare cancers.
Researchers developed a genomic risk assessment score to predict disease progression in patients with precursor conditions for multiple myeloma. The score assesses the severity of disease and risk of progression, allowing for more personalized care and early intervention strategies.
Researchers review clinical and scientific advances combining radiation therapy with immunotherapy to strengthen the immune response and improve disease control. The approach may offer new treatment options for patients facing hard-to-treat forms of bladder cancer.
Researchers developed a technique to analyze DNA methylation marks, identifying changes in blood production that occur with age. By age 50, many blood stem cells begin to drop out and larger clones take over, leading to a decline in diversity and resilience.
A randomized controlled trial found that additional imaging techniques such as fast MRI and contrast mammography can detect early-stage cancers in women with dense breasts that were missed by mammograms. The study showed a cancer detection rate of 1.7% for fast MRI and 1.9% for contrast mammography, compared to 0.4% for ultrasound.
A UCLA study found that selective serotonin reuptake inhibitors (SSRIs) can significantly enhance the ability of T cells to fight cancer and suppress tumor growth across various cancer types in mouse and human tumor models. SSRIs increased access to serotonin signals, making killer T cells happier and more effective at killing cancer c...
A rare form of childhood brain cancer called Diffuse Midline Glioma (DMG) hijacks gene control machinery to fuel its growth. A specific gene-silencing complex, CBX4/PCGF4-cPRC1, is essential for tumour growth and could be a promising drug target.
A systematic review and meta-analysis found elevated circPVT1 expression associated with poorer overall survival in patients with solid tumors. The study also revealed correlations between circPVT1 levels and larger tumor size, lymph node metastasis, distant metastasis, and advanced tumor-stage.
A study by Ludwig Princeton's Asael Roichman and Joshua Rabinowitz found that diet can alter cancer treatment outcomes, with certain plant-based foods influencing gut bacteria to clear PI3K inhibitors more quickly.
Researchers have developed a new treatment combining venetoclax and inobrodib that shows promising results in killing B-ALL cells, potentially reducing toxic chemotherapy needs. The approach could be less toxic than current treatments and effective in all age groups.
Researchers at MIT developed a method to quickly measure cell density, which can predict whether immunotherapies will work in patients or how tumors will respond to drug treatment. The technique uses a combined microfluidic device and fluorescent microscope to measure up to 30,000 cells in an hour.
Researchers at The University of Osaka found that localized oxygen deficiency in colon tumors can promote tumor growth by transforming normal fibroblasts into inflammatory fibroblasts. These altered cells release factors that help tumors grow, offering a potential new target for cancer therapy.
Researchers at UCSF found that certain gut bacteria can reduce chemotherapy side effects by clearing excess drugs and producing the protective vitamin K2. Patients with more beneficial bacteria had fewer side effects, suggesting that probiotics may help mitigate chemotherapy's impact.
UT Dallas bioengineers have created an enhanced light-activated immunotherapy approach to target advanced stomach cancer. Lab-designed molecules are primed with far-red or near-infrared light to activate the immune system against stubborn cancer cells, reducing side effects.
US survivors of adolescence and young adult cancer experience significantly worse mental health outcomes into middle age and older adulthood. Cancer clinicians should acknowledge this mental health burden and take steps to address it.
A recent study identifies LPCAT1 as a critical culprit in TNBC's aggressive behavior, which can be silenced with siRNA-delivering nanoparticles. This approach starves tumors of their energy supply, dramatically reducing tumor growth and lung metastasis.
A nationwide cohort study found that immune checkpoint inhibitors significantly increase the risk of myocarditis in NSCLC patients, with a 7.4-fold increase in risk compared to non-users. Cardiac monitoring for at least six months following ICI initiation is recommended.